INR 73.54
(1.56%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 46.15 Million INR | -26.05% |
2022 | 487.95 Million INR | 150.06% |
2021 | 195.13 Million INR | 115.03% |
2020 | 90.75 Million INR | -38.26% |
2019 | 146.99 Million INR | 11.84% |
2018 | 131.43 Million INR | 8.87% |
2017 | 120.72 Million INR | -5.16% |
2016 | 127.3 Million INR | 4.72% |
2015 | 121.56 Million INR | 1704.36% |
2014 | 6.73 Million INR | 0.0% |
2012 | 127.81 Million INR | -69.0% |
2011 | 412.24 Million INR | 142.91% |
2010 | 169.71 Million INR | -27.91% |
2009 | 235.42 Million INR | 71.0% |
2008 | 137.67 Million INR | -34.88% |
2007 | 211.41 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 95.78 Million INR | 39.82% |
2023 Q4 | 83.19 Million INR | -10.98% |
2023 Q3 | 93.45 Million INR | -39.5% |
2023 FY | 360.84 Million INR | -26.05% |
2023 Q1 | 144.89 Million INR | 0.51% |
2023 Q2 | 154.47 Million INR | 6.62% |
2022 Q1 | 54.16 Million INR | -16.37% |
2022 Q3 | 121.4 Million INR | 8.87% |
2022 Q4 | 144.15 Million INR | 18.74% |
2022 FY | 487.95 Million INR | 150.06% |
2022 Q2 | 111.51 Million INR | 105.89% |
2021 Q4 | 64.76 Million INR | 79.12% |
2021 FY | 195.13 Million INR | 115.03% |
2021 Q1 | 41.66 Million INR | 15.44% |
2021 Q3 | 36.16 Million INR | -31.19% |
2021 Q2 | 52.55 Million INR | 26.14% |
2020 Q2 | 3.39 Million INR | -85.68% |
2020 Q4 | 36.08 Million INR | 31.1% |
2020 Q1 | 23.73 Million INR | -18.7% |
2020 FY | 90.75 Million INR | -38.26% |
2020 Q3 | 27.52 Million INR | 710.09% |
2019 Q4 | 29.19 Million INR | -18.97% |
2019 FY | 146.99 Million INR | 11.84% |
2019 Q1 | 39.49 Million INR | 7.5% |
2019 Q3 | 36.03 Million INR | -14.78% |
2019 Q2 | 42.27 Million INR | 7.05% |
2018 FY | 131.43 Million INR | 8.87% |
2018 Q1 | 28.38 Million INR | -60.25% |
2018 Q4 | 36.73 Million INR | -10.73% |
2018 Q3 | 41.15 Million INR | 63.55% |
2018 Q2 | 25.16 Million INR | -11.36% |
2017 FY | 120.72 Million INR | -5.16% |
2017 Q4 | 71.41 Million INR | 38.6% |
2017 Q3 | 51.52 Million INR | 36.37% |
2017 Q2 | 37.78 Million INR | 32.51% |
2017 Q1 | 28.51 Million INR | -14.48% |
2016 Q1 | 24.44 Million INR | -13.9% |
2016 Q4 | 33.34 Million INR | 22.47% |
2016 Q3 | 27.22 Million INR | -7.26% |
2016 Q2 | 29.35 Million INR | 20.08% |
2016 FY | 127.3 Million INR | 4.72% |
2015 Q4 | 28.39 Million INR | 21.46% |
2015 Q3 | 23.37 Million INR | -3.8% |
2015 Q2 | 24.3 Million INR | -40.94% |
2015 Q1 | 41.14 Million INR | 131.94% |
2015 FY | 121.56 Million INR | 1704.36% |
2014 Q1 | 25.2 Million INR | 15.44% |
2014 FY | 6.73 Million INR | 0.0% |
2014 Q4 | 17.74 Million INR | 26.9% |
2014 Q3 | 13.98 Million INR | 417.78% |
2014 Q2 | 2.7 Million INR | -89.29% |
2013 Q4 | 21.83 Million INR | 4.02% |
2013 Q2 | 18.19 Million INR | 0.0% |
2013 Q3 | 20.98 Million INR | 15.37% |
2012 FY | 127.81 Million INR | -69.0% |
2012 Q2 | 43.29 Million INR | 0.0% |
2012 Q3 | 49.98 Million INR | 15.44% |
2011 Q4 | 102.51 Million INR | -4.48% |
2011 Q2 | 104.18 Million INR | 0.0% |
2011 FY | 412.24 Million INR | 142.91% |
2011 Q3 | 107.32 Million INR | 3.02% |
2010 FY | 169.71 Million INR | -27.91% |
2009 FY | 235.42 Million INR | 71.0% |
2008 Q4 | 55.66 Million INR | 0.0% |
2008 FY | 137.67 Million INR | -34.88% |
2007 FY | 211.41 Million INR | 0.0% |
2007 Q4 | 51.77 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 99.709% |
Hester Biosciences Limited | 908.84 Million INR | 94.921% |
Aarti Drugs Limited | 1.16 Billion INR | 96.047% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 98.499% |
Albert David Limited | 1.02 Billion INR | 95.502% |
Alembic Limited | 872.45 Million INR | 94.71% |
Alkem Laboratories Limited | 32.83 Billion INR | 99.859% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | 89.869% |
Bajaj HealthCare Limited | 985.34 Million INR | 95.316% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -576.774% |
Brooks Laboratories Limited | 51.18 Million INR | 9.816% |
Eris Lifesciences Limited | 4.94 Billion INR | 99.066% |
FDC Limited | 3.49 Billion INR | 98.681% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 99.603% |
Gufic Biosciences Limited | 1.18 Billion INR | 96.11% |
Hikal Limited | 4.46 Billion INR | 98.966% |
Ind-Swift Limited | 946.56 Million INR | 95.124% |
Innova Captab Limited | 931.03 Million INR | 95.042% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 97.903% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | 89.475% |
Jubilant Pharmova Limited | 14.45 Billion INR | 99.681% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 95.703% |
Lupin Limited | 125.09 Billion INR | 99.963% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | 71.549% |
Medico Remedies Limited | 59.67 Million INR | 22.654% |
Morepen Laboratories Limited | 1.98 Billion INR | 97.678% |
Nectar Lifesciences Limited | 932.7 Million INR | 95.051% |
Orchid Pharma Limited | 800.77 Million INR | 94.236% |
Procter & Gamble Health Limited | 2.99 Billion INR | 98.459% |
RPG Life Sciences Limited | 1.63 Billion INR | 97.178% |
Kilitch Drugs (India) Limited | 412.42 Million INR | 88.809% |
Sigachi Industries Limited | 579.88 Million INR | 92.041% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 98.193% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 96.71% |
Themis Medicare Limited | 1.12 Billion INR | 95.9% |
Unichem Laboratories Limited | 6.72 Billion INR | 99.314% |
Vaishali Pharma Limited | 84.02 Million INR | 45.071% |
Wanbury Limited | 978.96 Million INR | 95.285% |
Windlas Biotech Limited | 1 Billion INR | 95.414% |
ZIM Laboratories Limited | 1.01 Billion INR | 95.444% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 97.827% |
Ipca Laboratories Limited | 18.98 Billion INR | 99.757% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.97% |
Venus Remedies Limited | 1.91 Billion INR | 97.591% |
Sakar Healthcare Limited | 204.07 Million INR | 77.383% |
Aurobindo Pharma Limited | 55.65 Billion INR | 99.917% |
Divi's Laboratories Limited | 14.17 Billion INR | 99.674% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 98.134% |
Mankind Pharma Limited | 29.27 Billion INR | 99.842% |
Sequent Scientific Limited | 2.9 Billion INR | 98.409% |
Laurus Labs Limited | 11.9 Billion INR | 99.612% |
Neuland Laboratories Limited | 2.92 Billion INR | 98.425% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 99.688% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.902% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.963% |
Amrutanjan Health Care Limited | 2.09 Billion INR | 97.796% |
Wockhardt Limited | 8.48 Billion INR | 99.456% |
Bal Pharma Limited | 555.62 Million INR | 91.693% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.952% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 96.748% |
Par Drugs and Chemicals Limited | 58.28 Million INR | 20.814% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 97.877% |
Shilpa Medicare Limited | 3.33 Billion INR | 98.616% |
Valiant Laboratories Limited | 138.02 Million INR | 66.561% |
Ajanta Pharma Limited | 30.46 Billion INR | 99.848% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -224.745% |
Granules India Limited | 10.31 Billion INR | 99.552% |
Medicamen Biotech Limited | 335.16 Million INR | 86.229% |
Syncom Formulations (India) Limited | 345.63 Million INR | 86.646% |
Piramal Enterprises Limited | 63.65 Billion INR | 99.927% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.785% |
NATCO Pharma Limited | 10.05 Billion INR | 99.541% |
Suven Life Sciences Limited | 109.75 Million INR | 57.944% |
Strides Pharma Science Limited | 9.16 Billion INR | 99.496% |
Indoco Remedies Limited | 12.06 Billion INR | 99.617% |
Alpa Laboratories Limited | 127.38 Million INR | 63.765% |
Lasa Supergenerics Limited | 291.17 Million INR | 84.148% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 98.5% |